期刊
NEUROBIOLOGY OF DISEASE
卷 40, 期 2, 页码 378-385出版社
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.nbd.2010.06.013
关键词
A beta; Alzheimer's disease; GSK3 beta; Tau exon 10 splicing; SC35; Tauopathy; SH-SY5Y; Fronto-temporal dementia; Progressive supranuclear palsy; Corticobasal degeneration
资金
- Taipei Medical University Hospital [96TMU-TMUH-14]
- Shih Kong Wu Ho-Su Memorial Hospital [SKH-8302-98-NDR-08]
- National Science Council [94-2321-B-038-005, 97-2628-B-039 -002-MY3]
- Ministry of Education Topnotch Stroke Research Center
- Taiwan Department of Health Clinical Trial and Research Center of Excellence [DOH99-TD-B-111-004]
- Chi-Chin Huang Stroke Research Foundation
Amyloid-beta peptide (A beta) and Tau protein are the lead constituents in the pathogenesis of Alzheimer's disease (AD). However, their inter-relationship in the disease process remains to be established. Tauopathy refers to a characteristic neurodegenerative process in AD. In tauopathy, Tau accumulates as a consequence of altered pre-mRNA splicing of tau exon 10, resulting in 3R (without exon 10)/4R (with exon 10) imbalance. We studied A beta effects on tau exon 10 pre-mRNA splicing and relevant signaling events. This is the first demonstration of A beta alteration of tau exon 10 splicing with an increase in 3R/4R ratio caused by reduced 4R expression. This A beta action is causally related to its activation of GSK-3 beta which in turn phosphorylates SC35, an enhancer in tau exon 10 splicing. The establishment of the A beta-GSK-3 beta-SC35 cascade broadens insight into development of novel strategies to modulate A beta action on tau exon 10 splicing for possible prevention of tauopathy. (c) 2010 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据